Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675260 | 0.78 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL16675265 | 0.68 | KDM4E (0.31) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL16305057 | 0.67 | FFAR1 (0.54) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL12914952 | 0.66 | HMGCR (0.55) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL12745311 | 0.62 | NAALAD2 (0.46) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| Propionic Acid SCHEMBL7569705 | 0.59 | — | — | |
| SCHEMBL22898085 | 0.59 | KDM4E (0.50) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL17452117 | 0.59 | LMNA (0.48) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL7252624 | 0.58 | HMGCR (0.61) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| Bicarbonate SCHEMBL2938234 | 0.58 | TSHR (0.33) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | HMGCR 843/4885CHRM1 4737/4885TBXA2R 1702/4885 |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PELP1 | HMGCR 2397/4885CHRM1 4865/4885TBXA2R 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.